Garadacimab for hereditary angioedema (HAE)
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at how well a drug called garadacimab works and how safe it is for people with hereditary angioedema (HAE), a condition that causes sudden swelling. It tests the drug in people who are starting it for the first time as part of their regular care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years old or older.
- You have a confirmed diagnosis of hereditary angioedema (HAE) from a doctor or lab test.
- You are about to start taking garadacimab for the first time, as decided by your doctor.
- You can use a smartphone or computer to enter data for the study.
- You do not have another type of angioedema (like idiopathic or acquired) or angioedema with hives.
- You are not currently in any other research study involving experimental treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This program provides an experimental treatment called deucrictibant for people with hereditary angioedema (HAE) who have attacks that are not controlled by other approved medicines. It aims to see if this treatment can safely and effectively stop HAE attacks when other options have failed.
This trial tests an experimental medication called sebetralstat for treating angioedema attacks in children with hereditary angioedema (HAE). If your child is between 2 and 11 years old and has HAE, they may be able to join.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
Hear when a new Hereditary Angioedemas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.